CLINICAL TRIALS PROFILE FOR ESTRADERM

All Clinical Trials for ESTRADERM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00386022 ↗	The Effects of Aging and Estrogen on the Pituitary	Unknown status	National Institute on Aging (NIA)	Phase 2/Phase 3	2002-01-01	The purpose of this study is to study the effects of aging and estrogen on the brain. Specifically, this study will examine how the hypothalamus signals the pituitary gland to secrete reproductive hormones and how that changes with aging.
NCT00386022 ↗	The Effects of Aging and Estrogen on the Pituitary	Unknown status	Massachusetts General Hospital	Phase 2/Phase 3	2002-01-01	The purpose of this study is to study the effects of aging and estrogen on the brain. Specifically, this study will examine how the hypothalamus signals the pituitary gland to secrete reproductive hormones and how that changes with aging.
NCT01268046 ↗	Aging and Estrogen on Cortical Function	Completed	National Institute on Aging (NIA)	Phase 1/Phase 2	2009-11-01	This study will focus on how estrogen affects parts of the brain associated with memory and how the effect of estrogen is altered with aging in postmenopausal women.
NCT01268046 ↗	Aging and Estrogen on Cortical Function	Completed	Massachusetts General Hospital	Phase 1/Phase 2	2009-11-01	This study will focus on how estrogen affects parts of the brain associated with memory and how the effect of estrogen is altered with aging in postmenopausal women.

Clinical Trial Conditions for ESTRADERM

Condition Name

Condition Name for ESTRADERM
Intervention	Trials
Cognitive Changes	1
Healthy	1
Memory Loss	1
Postmenopausal Symptoms	1

Condition MeSH

Condition MeSH for ESTRADERM
Intervention	Trials
Memory Disorders	1
Amnesia	1
Pituitary Diseases	1

Clinical Trial Locations for ESTRADERM

Trials by Country

Trials by Country for ESTRADERM
Location	Trials
United States	2

Trials by US State

Trials by US State for ESTRADERM
Location	Trials
Massachusetts	2

Clinical Trial Progress for ESTRADERM

Clinical Trial Phase

Clinical Trial Phase for ESTRADERM
Clinical Trial Phase	Trials
Phase 2/Phase 3	1
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for ESTRADERM
Clinical Trial Phase	Trials
Completed	1
Unknown status	1

Clinical Trial Sponsors for ESTRADERM

Sponsor Name

Sponsor Name for ESTRADERM
Sponsor	Trials
National Institute on Aging (NIA)	2
Massachusetts General Hospital	2

Sponsor Type

Sponsor Type for ESTRADERM
Sponsor	Trials
NIH	2
Other	2

Last updated: June 4, 2026

Estraderm (estradiol) Clinical Trials Update, Market Analysis, and 2024–2032 Projection

Estraderm is an estradiol dermal patch brand. A complete, decision-grade update on current clinical trials, ongoing FDA regulatory status, and forward-looking market projections requires drug-specific sourcing (company pipeline listings, FDA product record/Orange Book entry, and payer or prescription datasets). No drug-specific trial/market dataset is present in the prompt, and producing an answer without those hard inputs would force fabrication.

What clinical trials are ongoing for Estraderm (estradiol patch) right now?

Not provided.

How do Estraderm trials compare by indication (HRT, menopausal symptoms, etc.)?

Not provided.

Are there Estraderm studies for skin delivery, patch adhesion, or pharmacokinetics?

Not provided.

What is the latest regulatory status of Estraderm in the US (FDA approval, Orange Book, exclusivity)?

Not provided.

What is the Orange Book status of Estraderm?

Not provided.

Has Estraderm exclusivity expired, and when does it lose exclusivity?

Not provided.

What patents protect Estraderm, and when do they expire?

Not provided.

How strong is the patent estate for Estraderm (composition, formulation, method-of-use, manufacturing)?

Not provided.

What generic entry risks exist for Estraderm (Paragraph IV, settlements, licensed generics)?

Not provided.

What litigation affects Estraderm (ANDA/PIV challenges, settlements, injunctions)?

Not provided.

What is Estraderm’s market size today, and where does demand come from?

Not provided.

How is the estradiol patch market segmenting by dose strength and generic vs branded share?

Not provided.

What are key payer dynamics for estradiol patches in major markets?

Not provided.

How does Estraderm compare with competing estradiol patch brands and generics?

Not provided.

Competitive landscape: which products substitute for Estraderm in formulary lists?

Not provided.

What delivery-system switching risks exist (patch vs gel vs oral)?

Not provided.

When will Estraderm’s revenue peak, and what is the 2024–2032 market projection?

Not provided.

Base case vs downside vs upside assumptions for Estraderm volume and price erosion

Not provided.

Key Takeaways

Not provided.

FAQs

1. Is Estraderm considered bioequivalent to other estradiol patches, and what drives switchability?
   Not provided.

2. Which countries have approved Estraderm, and what are the market-access bottlenecks?
   Not provided.

3. What are the main manufacturing and quality constraints for estradiol patch supply?
   Not provided.

4. What is the impact of estradiol patch safety communications on prescribing trends?
   Not provided.

5. How should investors underwrite Estraderm revenue under generic penetration scenarios?
   Not provided.

References (APA)

Not provided.